Pharmacology

Pharmacology (FAR/ZAA11)
Syllabus

Pharmacology 2 (FAR/ZAB11)
Syllabus
Exam Questions

Clinical Pharmacology (FAR/ZAA21)
Syllabus

Head of the Research Group

Prof. RNDr. Pavel Anzenbacher, DrSc.

1971-1991 Faculty of Sciences,  Charles University of Prague; 1991-1992 Academy of Sciences, Institute of Physiology, Prague, 1993-2001 Institute of Experimental Biopharmaceutics, joint Institute of the Academy of Sciences and PROMED, Hradec Králové;  since 2001 Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 2003-2014 Department Head.

Over 170 original papers, Web of Science over 190 papers and contributions, 5421without autocitations, H-index 31.

Research scope

Drug metabolism – various aspects. Enzymes – cytochromes P450 (CYP), enzymes of the 2nd phase of drug metabolism, comparison of properties of various liver microsomal CYP enzymes, properties of the active sites. Interactions of liver microsomal drug metabolizing system with drugs and xenobiotics, expression of proteins (CYPs, receptors etc.). Drug biotransformation, characterization of metabolites, determination of drug levels in biological matrices (e.g. plasma, biodistribution in organs). Microbiome and its role in drug metabolism

Ph.D. students (last ten years)

Alena Vanduchová (2018)

Kristýna Krasulová (2017)

Zuzana Matušková (2015)

Michaela Kopečná-Zapletalová (2015)

Michal Šiller (2010)

Jaroslav Matal (2009)

Jana Nekvindová (2008)

Grant projects

Earlier – examples

Mechanism of Modulation of Inflammatory Process, Drug Metabolism and Pharmacokinetics by Commensal and Probiotic Bacteria

Source: Czech Science Foudation

Coordination: Institute of Microbiology of the CAS, v. v. i.

Principal Investigator: MUDr. Miloslav Kverka, Ph.D. and Ing. Tomáš Hudcovic, Ph.D.

2012 – 2016

CZ.1.07/2.2.0.0/28.0088

Implementation of laboratory medicine to system of education at UP v Olomouc

Source: Ministry of Education Youth and Sports  (EC supported)

Principal Investigator: Prof. Dr. P. Anzenbacher, DrSc

2012-2014.

303/09/H048

Molecular Mechanismus of Selected Pathological Processes

Source: Czech Science Foundation

Principal Investigator: Prof. Dr. P. Anzenbacher, DrSc.

2009 – 2012

GA305/08/0535

Influence of Probiotics on Processes of Drug Pharmacokinetics

Source: Czech Science Foundation

Coordination: Institute of Experimental Medicine CAS

Principal Investigator: RNDr. Zdeněk Zídek, DrSc.

2008 – 2011

1P05OC065

Pleiotropic effects of hypolipidemics

Source: Ministry of Education Youth and Sports  and COST EC

2005 – 2009

Recent projects

AZV17-28231A

Expression of Enzymes of Biotransformation in Hepatocellular Carcinome

Source: Czech Health Research Council

Coordination: University Hospital Hradec Králové

Principal Investigator: RNDr. Jana Nekvindová, Ph.D.

2017-2020

17-09869S

Intestinal microbiome in Pharmacotherapy of GIT pathology

Source: Czech Science Foudation

Coordination: Institute of Microbiology of the CAS, v. v. i.

Principal Investigator: MUDr. Miloslav Kverka, Ph.D.

2017 – 2019

19-08294S 

Gut microbiota and host intestinal inflammation. Mechanism of bacterial and butyrate action in alleviating the consequences of dysbiosis

Coordination: Institute of Microbiology of the CAS, v. v. i.

Principal Investigator: Ing. Tomáš Hudcovic, CSc.

2019 - 2022

CZ.02.2:69/0.0/0.0/16_018/0002311and CZ.02.1.01/0.0/0.0/16_017/0002310

Ph.D. studies on Toxicology at UP Olomouc, Implementation and Infrastructural support

Source: Ministry of Education Youth and Sports (EC supported).¨

Principal Investigator: Prof. Dr. P. Anzenbacher, DrSc

2018-2021

Most important papers

Prokop J, Lněničková K, Cibiček N, Kosina P, Tománková V, Jourová L, Láníčková T, Skálová L, Szotáková B, Anzenbacher P, Zapletalová I, Rácová Z, Anzenbacherová E, Ulrichová J. Effect of bilberry extract (Vaccinium myrtillus L.) on drug-metabolizing enzymes in rats. Food Chem Toxicol. 2019 Jul;129:382-390. doi: 10.1016/j.fct.2019.04.051. Epub 2019 May 3.

Jourova L, Anzenbacher P, Matuskova Z, Vecera R, Strojil J, Kolar M, Nobilis M, Hermanova P, Hudcovic T, Kozakova H, Kverka M, Anzenbacherova E. Gut microbiota metabolizes nabumetone in vitro: Consequences for its bioavailability in vivo in the rodents with altered gut microbiome. Xenobiotica. 2019 Nov;49(11):1296-1302. doi: 10.1080/00498254.2018.1558310. Epub 2019 Feb 22.

Hyrsova L, Vanduchova A, Dusek J, Smutny T, Carazo A, Maresova V, Trejtnar F, Barta P, Anzenbacher P, Dvorak Z, Pavek P. Trans-resveratrol, but not other natural stilbenes occurring in food, carries the risk of drug-food interaction via inhibition of cytochrome P450 enzymes or interaction with xenosensor receptors. Toxicol Lett. 2019 Jan;300:81-91. doi: 10.1016/j.toxlet.2018.10.028. Epub 2018 Oct 27.

Šrejber M, Navrátilová V, Paloncýová M, Bazgier V, Berka K, Anzenbacher P, Otyepka M. Membrane-attached mammalian cytochromes P450: An overview of the membrane's effects on structure, drug binding, and interactions with redox partners. J Inorg Biochem. 2018 Jun;183:117-136. doi: 10.1016/j.jinorgbio.2018.03.002. Epub 2018 Mar 5. Review.

Krasulova K, Holas O, Anzenbacher P. Influence of Amlodipine Enantiomers on Human Microsomal Cytochromes P450: Stereoselective Time-Dependent Inhibition of CYP3A Enzyme Activity. Molecules. 2017 Nov 3;22(11). pii: E1879. doi: 10.3390/molecules22111879.

Nguyen LT, Myslivečková Z, Szotáková B, Špičáková A, Lněničková K, Ambrož M, Kubíček V, Krasulová K, Anzenbacher P, Skálová L. The inhibitory effects of β-caryophyllene, β-caryophyllene oxide and α-humulene on the activities of the main drug-metabolizing enzymes in rat and human liver in vitro. Chem Biol Interact. 2017 Dec 25;278:123-128.

Tomankova V, Anzenbacher P, Anzenbacherova E. Effects of obesity on liver cytochromes P450 in various animal models. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Jun;161(2):144-151.

Špičáková A, Szotáková B, Dimunová D, Myslivečková Z, Kubíček V, Ambrož M, Lněničková K, Krasulová K, Anzenbacher P, Skálová L. Nerolidol and Farnesol Inhibit Some Cytochrome P450 Activities but Did Not Affect Other Xenobiotic-Metabolizing Enzymes in Rat and Human Hepatic Subcellular Fractions. Molecules. 2017 Mar 24;22(4). pii: E509. doi: 10.3390/molecules22040509.

Jourová L, Anzenbacher P, Lišková B, Matušková Z, Hermanová P, Hudcovic T, Kozáková H, Hrnčířová L, Anzenbacherová E. Colonization by non-pathogenic bacteria alters mRNA expression of cytochromes P450 in originally germ-free mice.  Folia Microbiol (Praha). 2017 Nov;62(6):463-469.

Jourova L, Anzenbacher P, Anzenbacherova E. Human gut microbiota plays a role in the metabolism of drugs. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Sep;160(3):317-26

Matuskova Z, Anzenbacher P, Vecera R, Siller M, Tlaskalova-Hogenova H, Strojil J, Anzenbacherova E.  Effect of Lactobacillus casei on the Pharmacokinetics of Amiodarone in Male Wistar Rats. Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):29-36.

Tomankova V, Liskova B, Skalova L, Bartikova H, Bousova I, Jourova L, Anzenbacher P, Ulrichova J, Anzenbacherova E. Altered cytochrome P450 activities and expression levels in the liver and intestines of the monosodium glutamate-induced mouse model of human obesity. Life Sci. 2015 Jul 15;133:15-20.

Boušová I, Matoušková P, Bártíková H, Szotáková B, Hanušová V, Tománková V, Anzenbacherová E, Lišková B, Anzenbacher P, Skálová L. Influence of diet supplementation with green tea extract on drug-metabolizing enzymes in a mouse model of monosodium glutamate-induced obesity. Eur J Nutr. 2016 Feb;55(1):361-71.

Novotná A, Krasulová K, Bartoňková I, Korhoňová M, Bachleda P, Anzenbacher P, Dvořák Z. Dual effects of ketoconazole cis-enantiomers on CYP3A4 in human hepatocytes and HepG2 Cells. PLoS One. 2014 Oct 24;9(10):e111286.

Nekvindova J, Contreras JA, Juvan P, Fon Tacer K, Anzenbacher P, Zidek Z, Kopecna Zapletalova M, Rozman D, Anzenbacherova E. Acyclic nucleoside phosphonates: a study on cytochrome P450 gene expression. Xenobiotica. 2014 Aug;44(8):708-15.

Matuskova Z, Anzenbacherova E, Vecera R, Tlaskalova-Hogenova H, Kolar M, Anzenbacher P. Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats. PLoS One. 2014 Feb 5;9(2):e87150. doi: 10.1371/journal.pone.0087150. eCollection 2014.

Srovnalova A, Svecarova M, Zapletalova MK, Anzenbacher P, Bachleda P, Anzenbacherova E, Dvorak Z. Effects of anthocyanidins and anthocyanins on the expression and catalytic activities of CYP2A6, CYP2B6, CYP2C9, and CYP3A4 in primary human hepatocytes and human liver microsomes. J Agric Food Chem. 2014 Jan 22;62(3):789-97.

Anzenbacher P, Zanger U (Editors) Metabolism of Drugs and Other Xenobiotics. Wiley-VCH, Weinheim 2012.

Head of the Research Group

Prof. RNDr. Pavel Anzenbacher, DrSc.

1971-1991 Faculty of Sciences,  Charles University of Prague; 1991-1992 Academy of Sciences, Institute of Physiology, Prague, 1993-2001 Institute of Experimental Biopharmaceutics, joint Institute of the Academy of Sciences and PROMED, Hradec Králové;  since 2001 Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 2003-2014 Department Head.

Over 170 original papers, Web of Science over 190 papers and contributions, 5421 citions without autocitations,  H-index 31.

Studies on the interaction of xenobiotics incl. drugs with liver microsomal system of biotransformation, inhibition of this system, focus on cytochromes P450, isolation of CYPs, studies on the structure of CYPs, localization in the membranes, flexibility of the active site determining the interaction with xenobiotics, experimental models of CYPs, influence of xenobiotics on the activity and expression of proteins, estimation of clinically important interactions of drugs and xenobiotics. Determination of the levels of xenobiotics in samples of biological origin.

Ph.D. students (last ten years)

Alena Vanduchová (2018)

Kristýna Krasulová (2017)

Zuzana Matušková (2015)

Michaela Kopečná-Zapletalová (2015)

Michal Šiller (2010)

Jaroslav Matal (2009)

Jana Nekvindová (2008)

Recent grant projects

CZ.02.2.69/0.0/0.0/16

Toxicology

Source: Ministry of Education, Youth and Sports and EC

Principal Investigator: Prof. Dr. P. Anzenbacher, DrSc.

2017-2021

CZ.02.1.01/0.0/0.0/16

Toxicology

Source: Ministry of Education, Youth and Sports and EC

Principal Investigator: Prof. Dr. P. Anzenbacher, DrSc.

2017-2021.

P303/12/G163

Center of  Excellence: Center of Interactions of Food Supplements with Drugs and of Nutrigenetics

Source: Grant Agency of the Czech Republic

Coordinator: Charles University Prague

Principal Investigator: Prof. PharmDr. Petr Pávek, Ph.D.

2012 – 2018

13-01809S

Enantiospecific interactions between clinically important drugs and regulation of CYPs Poskytovatel: Source: Grant Agency of the Czech Republic

Principal Investigator: prof. RNDr. Zdeněk Dvořák, Ph.D.,

2013 – 2017

Important papers – last years

Krasulova K, Holas O, Anzenbacher P. Influence of Amlodipine Enantiomers on Human Microsomal Cytochromes P450: Stereoselective Time-Dependent Inhibition of CYP3A Enzyme Activity. Molecules. 2017 Nov 3;22(11). pii: E1879. doi: 10.3390/molecules22111879.

Nguyen LT, Myslivečková Z, Szotáková B, Špičáková A, Lněničková K, Ambrož M, Kubíček V, Krasulová K, Anzenbacher P, Skálová L. The inhibitory effects of β-caryophyllene, β-caryophyllene oxide and α-humulene on the activities of the main drug-metabolizing enzymes in rat and human liver in vitro. Chem Biol Interact. 2017 Dec 25;278:123-128.

Tomankova V, Anzenbacher P, Anzenbacherova E. Effects of obesity on liver cytochromes P450 in various animal models. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Jun;161(2):144-151.

Špičáková A, Szotáková B, Dimunová D, Myslivečková Z, Kubíček V, Ambrož M, Lněničková K, Krasulová K, Anzenbacher P, Skálová L. Nerolidol and Farnesol Inhibit Some Cytochrome P450 Activities but Did Not Affect Other Xenobiotic-Metabolizing Enzymes in Rat and Human Hepatic Subcellular Fractions. Molecules. 2017 Mar 24;22(4). pii: E509.

Jourová L, Anzenbacher P, Lišková B, Matušková Z, Hermanová P, Hudcovic T, Kozáková H, Hrnčířová L, Anzenbacherová E. Colonization by non-pathogenic bacteria alters mRNA expression of cytochromes P450 in originally germ-free mice.  Folia Microbiol (Praha). 2017 Nov;62(6):463-469.

Jourova L, Anzenbacher P, Anzenbacherova E. Human gut microbiota plays a role in the metabolism of drugs. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Sep;160(3):317-26.

Matuskova Z, Anzenbacher P, Vecera R, Siller M, Tlaskalova-Hogenova H, Strojil J, Anzenbacherova E.  Effect of Lactobacillus casei on the Pharmacokinetics of Amiodarone in Male Wistar Rats. Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):29-36.

Tomankova V, Liskova B, Skalova L, Bartikova H, Bousova I, Jourova L, Anzenbacher P, Ulrichova J, Anzenbacherova E. Altered cytochrome P450 activities and expression levels in the liver and intestines of the monosodium glutamate-induced mouse model of human obesity. Life Sci. 2015 Jul 15;133:15-20. 

Research Group Leader
Prof. MUDr. Rostislav Večeřa, Ph.D.

1989-1994 Institute of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University Olomouc, since 1994 Department of Pharmacology, Faculty of Medicine and Dentistry, Palacký University Olomouc
In total over 60 original papers, in Web of Science 589 citations without self-citations, H-index 15

Research characteristics
Study of hypolipidemic, antioxidant and pleiotropic effects of natural substances and extracts in experimental models of rats with metabolic syndrome. Research on influencing the components of metabolic syndrome and enzymes of drug metabolism (cytochromes P450) by these substances and extracts. Study of pharmacokinetics and organ distribution of natural compounds. Experimental pharmacology of sepsis and inflammation, pharmacokinetics of potential antibacterial drugs.

Ph.D. students

Martin Poruba (2019)
Alice Zachařová (2013)
Jan Orolin (2007)
 
Solved grant projects
 
17-08888S
Project name: Effect of silymarin in combination with hypolipidemics drugs on mechanisms leading to lipid accumulation, oxidative stress and inflammation in the metabolic syndrome
The Czech Science Foundation
Research years: 2017-2019
 
13-10813S
Project name: Natural polyphenolic compounds in experimental pharmacology of metabolic syndrome
The Czech Science Foundation
Research years: 2013-2016
 
305/09/1177
Project name: Pleiotropic effects of hypolipidemics
The Czech Science Foundation
Research years: 2009-2011
 
Projects in which the research group participates
 
17-29680A
Project name: Use of lipophosphonoxins to prevent and treat musculoskeletal infections: the potential role of new antibacterial agents
The Czech Health Research Council
Main beneficiary: Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences
Research leader: ing. Dominik Rejman, CSc.
Research years: 2017-2020
 
15-22248S
Project name: Study of overcoming bacterial resistance by combining antibiotics with nanoparticles and silver compounds by in vitro, in vivo and in silico methods
The Czech Science Foundation
Main beneficiary: Palacký University in Olomouc
Research leader: RNDr. Aleš Panáček Ph.D.
Research years: 2015-2017
 
P304 / 10/1316
Project name: In vitro and in vivo determination of antimicrobial activity and toxicity of silver nanoparticles and nanocomposites and materials based on silver nanoparticles
The Czech Science Foundation
Main beneficiary: Palacký University in Olomouc
Research leader: RNDr. Aleš Panáček Ph.D.
Research years: 2010-2013
 
The most important publications

Poruba M., Matuskova Z., Hüttl M., Malinska H., Oliyarnyk O., Markova I., Gurska S., Kazdova L., Vecera R.: Fenofibrate Decreases Hepatic P-Glycoprotein in a Rat Model of Hereditary Hypertriglyceridemia. Front. Pharmacol. 2019,  doi: 10.3389/fphar.2019.00056. eCollection.

Malinska H., Hüttl M., Oliyarnyk O., Markova I., Poruba M., Racova Z., Kazdova L., Vecera R.: Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome. Plos One 2019; 14(8): e0220377. doi: 10.1371/journal.pone.0220377. eCollection.

Cibiček N, Ehrman J, Prošková J, Večeřa R. Critical evaluation of colon submucosal microdialysis in awake, mobile rats. Plos One 2018, 13(1). doi: 10.1371/journal.pone.0191041.

Poruba M, Kazdova L, Oliyarnyk O, Malinska H, Matuskova Z, Tozzi di Angelo I, Skop V, Vecera R. Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome. Xenobiotica 2015, 45(9): 751-756.

Marhol P, Bednář P, Kolářová P, Večeřa R, Ulrichová J, Tesařová E, Vavříková E, Kuzma M, Křen V. Pharmacokinetics of pure silybin diastereoisomers and identification of thein metabolites in rat plasma. Journal of functional foods 2015 14: 570-580.

Vecera R, Zacharova A, Kazdova L, Matuskova Z, Skottova N, Strojil J, Oliyarnyk O, Anzenbacher P. Silybin affects the liver microsomal CYP2C6 in HHTg rats. Biomedical Papers. 2013 Vol 157, Suppl. 1: 60-64.

Zachařová A, Šiller M, Špičáková A, Anzenbacherová E, Škottová N, Anzenbacher P, Večeřa R. Rosuvastatin suppressest he liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. Xenobiotica 2012, 42(8): 731-736.

Zachařová A, Siller M, Spičáková A, Anzenbacherová E, Skottová N, Anzenbacher P, Večeřa R. Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. Xenobiotica. 2012 Aug; 42(8):731-6.

Večeřa R, Zachařová A, Orolin J, Strojil J, Skottová N, Anzenbacher P. Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat. Biopharm Drug Dispos. 2011 Nov; 32(8):482-7.

Head of the Research Programme

Doc. MUDr. Karel Urbánek, Ph.D.

From 1994 at the Department of Pharmacology Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc

A total of 40 original research papaers, 410 citations in the Web of Science (without self-citations), H-index 12

Programme Characteristics

Pharmacokonetic studies in special populations, pharmacokinetic modelling and therapeutic drug monitoring. Pharmacoltherapy in children. Adverse drug reactions in clinical praxis. Medication erros in nurcing. Drug utilization research and pharmacoepidemilogy.

Postgraduate students

Vendula Kubíčková

Šárka Sperottová

Pavlína Štrbová

Hana Suchánková (2017)

Jan Strojil (2014)

Petra Matalová (2014)

Vladimíra Vojtová (2012)

Grant projects

17-31540A

Project: Population pharmacokinetics of antibiotic prophylaxis during cardiac surgery with

cardiopulmonary bypass

Provider: Agentura pro zdravotnický výzkum České republiky

Project period: 2017-2021

Shared Research Projects

NS 10309-3/2009

Project: Changes of vancomycin and gentamicine pharmacokinetics in continuous and intermittent elimination methods in sepsis and akuce kidney Indry; use od predictive pharmacokinetic modelling of antibiotik dosing

Provider: Interní grantová agentura Ministerstva zdravotnictví České republiky

Principal research institution : Fakultní nemocnice Olomouc

Principal investigator: MUDr. Jana Zahálková, Ph.D.

Project period:: 2009 - 2011

Important Research Papers

Suchánková H, Lipš M, Urbánek K, Neely MN, Strojil J. Is continuous infusion of imipenem always the best choice? Int J Antimicrob Agents. 2017 Mar; 49(3):348-354.

Štrbová P, Šiller M, Urbánek K, Poruba M. Residual volumes and final weights in different types of plastic infusion containers. International Journal of Pharmacy and Pharmaceutical Sciences 2016, 3 (8): 293-296.

Lipš M, Siller M, Strojil J, Urbánek K, Balík M, Suchánková H. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. Int J Antimicrob Agents. 2014 Oct; 44(4):358-62.

Matalová P, Urbánek K, Anzenbacher P. Specific features of pharmacokinetics in children. Drug Metab Rev. 2016; 48(1):70-9.

Langerová P, Vrtal J, Urbánek K. Adverse drug reactions causing hospital admissions in childhood: a prospective, observational, single-centre study. Basic Clin Pharmacol Toxicol. 2014 Dec; 115(6):560-4.

Langerová P, Vrtal J, Urbánek K. Incidence of unlicensed and off-label prescription in children. Ital J Pediatr. 2014 Feb 4; 40:12.

Langerová P, Prokeš M, Konvalinka M, Fürstová J, Urbánek K. Incidence of potential drug interactions in medication prescriptions for children and adolescents in the University Hospital Olomouc, Czech Republic. Eur J Pediatr. 2013 May; 172(5):631-8.

Vojtová V, Kolár M, Hricová K, Uvízl R, Neiser J, Blahut L, Urbánek K. Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units. New Microbiol. 2011 Jul; 34(3):291-8.

Vinklerová I, Procházka M, Procházka V, Urbánek K. Incidence, severity, and etiology of drug-induced acute pancreatitis. Dig Dis Sci. 2010 Oct; 55(10):2977-81.

Book Chapters

Urbánek K, Krystyník O, Procházka V. Drug-induced cholestatic liver injury. In: Novotny JF, Sedlacek F. Bilirubin: Chemistry, Regulation and Disorder. Nova Science Publishers, Inc., New York, 2012; pp. 79-294. ISBN: 978-1-62100-911-5.

Urbánek K, Vinklerová I, Krystyník O, Procházka V. Acute Pancreatitis Induced by Drugs, In: Rodrigo L (Ed.), Acute Pancreatitis. InTech, Rijeka, 2011, pp. 17 - 34. ISBN 978-953-307-984-4.